/   Home   /   Newsroom   /   News Updates

Chinese Scientists Develop Tumor-specific Anti-cancer Therapy

Jul 15, 2019     Email"> PrintText Size

Chinese scientists developed a combined tumor-killing therapy that can be activated specifically at tumor sites in mouse models of cancer, which is more effective than previous similar therapies.  

The study published on Friday in the journal Science Immunology described the new cancer immunotherapy that can prevent the immune system from becoming tolerant of tumors, which occurs in 30 percent of all cancer patients.  

A team led by Prof. YU Haijun and Prof. LI Yaping from the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences developed a common immune checkpoint inhibitor in a nanoparticle formulation, which is highly tumor-specific.  

The checkpoint inhibitor is a kind of increasingly popular anti-tumor drug. It can block proteins that keep immune T cells from killing cancer. But the checkpoint inhibitor used to target those immune system-suppressing proteins like PD-1 and PD-L1 often fails to reach deep-seated or metastatic tumors.  

YU and LI's team combined the nanoparticles carrying PD-L1-targeting antibodies with a light-activated molecule. The molecule called photosensitizer can produce tumor-killing reactive oxygen species after encountering a protein abundant in tumors, according to the study.  

In mouse models, a local near-infrared radiation that activated the photosensitizer, along with the administration of antibodies-carrying nanoparticles, promoted the infiltration of cancer cell-killing T cells into the tumor site and made the tumors more sensitive to the checkpoint blockade.  

This combination also helped the nanoparticles effectively suppress tumor growth and metastasis to the lung and lymph nodes, resulting in approximately 80 percent mouse survival over 70 days, compared to complete mouse death in 45 days in the group treated with only PD-L1 antibodies, according to the study. (Xinhua)  

(Editor: LI Yuan)


YU Haijun; LI Yaping

Shanghai Institute of Materia Medica

Phone: 86-21-50802322; 86-21-20231000-1515
E-mail: hjyu@simm.ac.cn; ypli@simm.ac.cn

Related Articles

nanocomposite;cancer therapy;nanocomposite

Scientists Develop A New Nanocomposite to Assist Diagnosis and Therapy of Cancer

Dec 25, 2018

A joint team from Institute of Technical Biology and Agriculture Engineering, Hefei Institutes of Physical Science and Shanghai Jiao Tong University developed a new nanocomposite that could be theranostic agent for effectively diagnosis and combinatori...

ATR kinase;cancer;cancer therapy;DNA demage

Chinese Researchers Map Key Protein in DNA Repair with Near-atomic Resolution

Dec 04, 2017

Chinese researchers have determined the near-atomic structure of a protein crucial for repairing damaged DNA, an advance that may shed light on novel effective cancer therapies. Cells in our body continuously replicate to repair and replace damaged tis...

homoserine lactone;apoptosis;mitochondrial;cancer therapy;ROS

Study May Reveal A New Potential Candidate for Cancer Therapy

Sep 18, 2018

Chinese scientists from Institute of Technical Biology and Agriculture Engineering investigated how homoserine lactone, or C12 exerts its pro-apoptotic and anti-tumor effects in vivo and further demonstrated that it could be a potential candidate to as...

Contact Us

Copyright © 2002 - Chinese Academy of Sciences